-
2024-516612-16-00
4
2020-06-17
gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET)
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2023-508128-37-00
5
2017-07-19
All patients who have been treated with Novartis or Penn CAR T-cell th
-
2023-505625-14-00
7
2017-01-31
Relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r NHL)
-
2023-503539-16-00
5
2025-11-11
Non-small Cell Lung Cancer (NSCLC)
-
2025-521249-25-00
7
2025-10-30
MTAP-deleted advanced or metastatic solid tumors
-
2024-516909-23-00
4
2025-10-28
Locally Advanced Resectable Gastroesophageal Adenocarcinoma
-
2024-516473-72-00
5
2025-07-31
Multifocal Motor Neuropathy
-
2024-519575-26-00
4
2025-07-25
Chronic pulmonary aspergillosis (CPA)
-
2024-518998-33-00
5
2025-07-23
Ulcerative Colitis
-
2024-520062-54-00
4
2025-07-23
Chronic Hepatitis D Virus (HDV) Infection
-
2024-513282-39-00
5
2025-05-28
Hidradenitis Suppurativa (HS)
-
2024-515907-20-00
9
2025-05-23
Primary biliary cholangitis (PBC)
-
2023-506842-22-00
7
2025-05-19
Recurrent endometrial cancer, recurrent epithelial ovarian, fallopian
-
2024-517741-14-00
9
2025-04-22
advanced non-squamous non-small cell lung cancer (NSCLC)
-
2024-513210-36-00
5
2025-04-04
Chronic Spontaneous Urticaria
-
2024-513738-39-00
9
2025-03-18
IDH1-mutant Glioma
-
2024-512180-31-00
4
2025-03-14
Oligometastatic renal cell carcinoma
-
2024-511253-21-00
3
2025-02-28
Thoracic tumors with homozygous MTAP-deletion
-
2024-512998-27-00
5
2025-02-21
Non-Small Cell Lung Cancer
-
2023-505394-32-00
5
2025-02-06
chronic graft versus host disease
-
2024-510849-34-00
4
2025-02-04
Eosinophilic Esophagitis
-
2024-514137-38-00
4
2025-02-04
Severe refractory idiopathic inflammatory myopathies (IIM)